# CRLF2

## Overview
CRLF2, or cytokine receptor-like factor 2, is a gene that encodes a transmembrane protein involved in cytokine receptor signaling. The CRLF2 protein forms a heterodimer with the interleukin-7 receptor (IL7R) to mediate the signaling of thymic stromal lymphopoietin (TSLP), which is essential for the proliferation and differentiation of B-cells and the activation of immune responses (van2012Differences). This receptor complex is crucial for the activation of the JAK-STAT signaling pathway, which promotes cell proliferation and survival (van2012Differences). CRLF2 is particularly significant in the context of hematological malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL), where its overexpression or mutation can lead to aberrant signaling and poor clinical outcomes (Harvey2010Rearrangement; Chen2012Outcome). The gene's role in immune function and its implications in disease make it a critical focus of research in oncology and immunology.

## Structure


## Function
CRLF2 (cytokine receptor-like factor 2) is a protein that plays a significant role in the signaling pathways of thymic stromal lymphopoietin (TSLP) in healthy human cells. It forms a heterodimer with the interleukin-7 receptor (IL7R) to mediate TSLP signaling, which is crucial for the proliferation and differentiation of B-cells. This signaling pathway supports B-cell development by acting as a growth factor (van2012Differences). The CRLF2/IL7R complex is involved in the activation of JAK1 and JAK2 kinases, leading to the phosphorylation of STAT transcription factors, which promote cell proliferation and survival (van2012Differences).

CRLF2 is also implicated in immune responses, particularly in the activation of myeloid dendritic cells and CD4+ T cells. In these cells, TSLP robustly stimulates the phosphorylation of STAT transcription factors, which are crucial for immune signaling (van2012Differences). The CRLF2 protein is primarily active in the cell membrane, where it interacts with other proteins to mediate these immune responses. Its expression is tightly regulated under normal physiological conditions, ensuring proper immune function and cell development (van2012Differences).

## Clinical Significance
CRLF2 (cytokine receptor-like factor 2) is implicated in various hematological malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL). Alterations in CRLF2 expression, such as overexpression or genomic rearrangements, are associated with poor outcomes in high-risk pediatric B-ALL. These alterations often involve translocations like IGH@-CRLF2 and fusions such as P2RY8-CRLF2, which are linked to increased CRLF2 expression and poor prognosis (Harvey2010Rearrangement; Chen2012Outcome).

In Down syndrome-associated acute lymphoblastic leukemia (DS-ALL), CRLF2 is frequently overexpressed, with studies showing that 62.1% of DS-ALL cases exhibit increased CRLF2 expression. This overexpression is often due to chromosomal translocations or interstitial deletions (Ensor2011Demographic; Hertzberg2010Down). CRLF2 overexpression in DS-ALL is commonly associated with JAK2 mutations, which can lead to constitutive activation of the JAK-STAT signaling pathway, contributing to leukemogenesis (Hertzberg2010Down; Hassan2022Prognostic).

CRLF2 rearrangements are also associated with specific ethnicities, such as Hispanic/Latino, and often co-occur with other genetic alterations like IKZF1 deletions, further complicating the disease's prognosis (Harvey2010Rearrangement). These genetic interactions highlight the complex role of CRLF2 in the pathogenesis of B-ALL and DS-ALL.

## Interactions
CRLF2, a cytokine receptor subunit, is involved in several critical protein interactions, particularly in the context of B-cell acute lymphoblastic leukemia (B-ALL). It forms a heterodimer with the interleukin-7 receptor alpha chain (IL7Rα) to bind thymic stromal lymphopoietin (TSLP), which is essential for signaling pathways that support B-cell development (Pandey2000Cloning). This interaction is crucial for the activation of the JAK-STAT signaling pathway, a key pathway in cytokine receptor signaling (Yoda2009Functional).

CRLF2 also interacts with JAK2, a kinase involved in cytokine receptor signaling. It can form complexes with both wild-type and mutant forms of JAK2, such as the gain-of-function mutant JAK2 R683G, which is significant in certain leukemias (van2012Differences). The interaction between CRLF2 and JAK2 is crucial for the activation of downstream signaling pathways, including the phosphorylation of STAT5 (van2012Differences).

Mutations in CRLF2, such as Phe232Cys, promote constitutive dimerization and cytokine-independent signaling, further highlighting its role in aberrant signaling in B-ALL (Yoda2009Functional). These interactions underscore the importance of CRLF2 in the pathogenesis of certain leukemias.


## References


[1. (Pandey2000Cloning) Akhilesh Pandey, Katsutoshi Ozaki, Heinz Baumann, Steven D. Levin, Anne Puel, Andrew G. Farr, Steven F. Ziegler, Warren J. Leonard, and Harvey F. Lodish. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nature Immunology, 1(1):59–64, July 2000. URL: http://dx.doi.org/10.1038/76923, doi:10.1038/76923. This article has 339 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/76923)

[2. (Hertzberg2010Down) Libi Hertzberg, Elena Vendramini, Ithamar Ganmore, Gianni Cazzaniga, Maike Schmitz, Jane Chalker, Ruth Shiloh, Ilaria Iacobucci, Chen Shochat, Sharon Zeligson, Gunnar Cario, Martin Stanulla, Sabine Strehl, Lisa J. Russell, Christine J. Harrison, Beat Bornhauser, Akinori Yoda, Gideon Rechavi, Dani Bercovich, Arndt Borkhardt, Helena Kempski, Geertruy te Kronnie, Jean-Pierre Bourquin, Eytan Domany, and Shai Izraeli. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of crlf2 is associated with mutated jak2: a report from the international bfm study group. Blood, 115(5):1006–1017, February 2010. URL: http://dx.doi.org/10.1182/blood-2009-08-235408, doi:10.1182/blood-2009-08-235408. This article has 269 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2009-08-235408)

[3. (Harvey2010Rearrangement) Richard C. Harvey, Charles G. Mullighan, I-Ming Chen, Walker Wharton, Fady M. Mikhail, Andrew J. Carroll, Huining Kang, Wei Liu, Kevin K. Dobbin, Malcolm A. Smith, William L. Carroll, Meenakshi Devidas, W. Paul Bowman, Bruce M. Camitta, Gregory H. Reaman, Stephen P. Hunger, James R. Downing, and Cheryl L. Willman. Rearrangement of crlf2 is associated with mutation of jak kinases, alteration of ikzf1, hispanic/latino ethnicity, and a poor outcome in pediatric b-progenitor acute lymphoblastic leukemia. Blood, 115(26):5312–5321, July 2010. URL: http://dx.doi.org/10.1182/blood-2009-09-245944, doi:10.1182/blood-2009-09-245944. This article has 446 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2009-09-245944)

[4. (Yoda2009Functional) Akinori Yoda, Yuka Yoda, Sabina Chiaretti, Michal Bar-Natan, Kartik Mani, Scott J. Rodig, Nathan West, Yun Xiao, Jennifer R. Brown, Constantine Mitsiades, Martin Sattler, Jeffrey L. Kutok, Daniel J. DeAngelo, Martha Wadleigh, Alfonso Piciocchi, Paola Dal Cin, James E. Bradner, James D. Griffin, Kenneth C. Anderson, Richard M. Stone, Jerome Ritz, Robin Foà, Jon C. Aster, David A. Frank, and David M. Weinstock. Functional screening identifies crlf2 in precursor b-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences, 107(1):252–257, December 2009. URL: http://dx.doi.org/10.1073/pnas.0911726107, doi:10.1073/pnas.0911726107. This article has 278 citations.](https://doi.org/10.1073/pnas.0911726107)

[5. (van2012Differences) Diederik van Bodegom, Jun Zhong, Nadja Kopp, Chaitali Dutta, Min-Sik Kim, Liat Bird, Oliver Weigert, Jeffrey Tyner, Akhilesh Pandey, Akinori Yoda, and David M. Weinstock. Differences in signaling through the b-cell leukemia oncoprotein crlf2 in response to tslp and through mutant jak2. Blood, 120(14):2853–2863, October 2012. URL: http://dx.doi.org/10.1182/blood-2012-02-413252, doi:10.1182/blood-2012-02-413252. This article has 38 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2012-02-413252)

[6. (Ensor2011Demographic) Hannah M. Ensor, Claire Schwab, Lisa J. Russell, Sue M. Richards, Heather Morrison, Dino Masic, Lisa Jones, Sally E. Kinsey, Ajay J. Vora, Christopher D. Mitchell, Christine J. Harrison, and Anthony V. Moorman. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and crlf2 deregulation: results from the mrc all97 clinical trial. Blood, 117(7):2129–2136, February 2011. URL: http://dx.doi.org/10.1182/blood-2010-07-297135, doi:10.1182/blood-2010-07-297135. This article has 114 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2010-07-297135)

[7. (Hassan2022Prognostic) Naglaa M. Hassan, Mona S. Abdellateif, Enas M. Radwan, Sayed Abed Hameed, Eman D. El Desouky, Mahmoud M. Kamel, and Abdallah M. Gameel. Prognostic significance of crlf2 overexpression and jak2 mutation in egyptian pediatric patients with b-precursor acute lymphoblastic leukemia. Clinical Lymphoma Myeloma and Leukemia, 22(6):e376–e385, June 2022. URL: http://dx.doi.org/10.1016/j.clml.2021.12.006, doi:10.1016/j.clml.2021.12.006. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.clml.2021.12.006)

[8. (Chen2012Outcome) I-Ming Chen, Richard C. Harvey, Charles G. Mullighan, Julie Gastier-Foster, Walker Wharton, Huining Kang, Michael J. Borowitz, Bruce M. Camitta, Andrew J. Carroll, Meenakshi Devidas, D. Jeanette Pullen, Debbie Payne-Turner, Sarah K. Tasian, Shalini Reshmi, Catherine E. Cottrell, Gregory H. Reaman, W. Paul Bowman, William L. Carroll, Mignon L. Loh, Naomi J. Winick, Stephen P. Hunger, and Cheryl L. Willman. Outcome modeling with crlf2, ikzf1, jak, and minimal residual disease in pediatric acute lymphoblastic leukemia: a children’s oncology group study. Blood, 119(15):3512–3522, April 2012. URL: http://dx.doi.org/10.1182/blood-2011-11-394221, doi:10.1182/blood-2011-11-394221. This article has 188 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2011-11-394221)